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Filling Pressures and Collagen Metabolism in Hypertensive
Patients With Heart Failure and Normal Ejection Fraction
Arantxa Gonza´lez, Begon˜a Lo´pez, Ramo´n Querejeta, Elena Zubillaga, Toma´s Echeverría, Javier Díez
Abstract—This study was designed to evaluate the association between circulating biomarkers of collagen metabolism and
elevated left-sided filling pressures (FPs), as assessed from elevated estimated pulmonary capillary wedge pressure
(ePCWP), in hypertensive patients with heart failure with normal ejection fraction. Echocardiography was performed
and ePCWP was calculated from the formula ePCWP1.901.24(maximum early transmitral flow velocity in
diastole:tissue Doppler early mitral annulus velocity). The biomarkers of collagen synthesis (carboxy-terminal
propeptide of procollagen type I) and degradation (matrix metalloproteinase [MMP] 1 and tissue inhibitor of MMP-1
[TIMP-1]) were analyzed by ELISA methods. Seventy-eight patients with normal FPs (ePCWP 15 mm Hg) and 78
with elevated FPs (ePCWP 15 mm Hg) were included. Compared with controls, the levels of the 3 biomarkers were
increased in the 2 groups of patients. The MMP-1:TIMP-1 ratio, an index of MMP-1 activity, was increased in patients
with normal FPs and unchanged in patients with elevated FPs. Patients with elevated FPs exhibited higher TIMP-1 levels
and a lower MMP-1:TIMP-1 ratio than patients with normal FPs. ePCWP was independently associated with TIMP-1
(r0.349; P0.001) and the MMP-1:TIMP-1 ratio (r0.240; P0.01) in all of the patients. Receiver operating
characteristic curves showed that a cutoff value of TIMP-1 of 1557 ng/mL provided 64% sensitivity and 67% specificity
for predicting elevated FPs with a relative risk of 3.71 (95% CI: 1.91 to 7.22). These findings suggest that, in
hypertensive patients with heart failure with normal ejection fraction and elevated FPs, collagen synthesis predominates
over degradation because of a relative excess of TIMP-1. This imbalance can facilitate myocardial fibrosis, which, in
turn, may contribute to the elevation of FPs in these patients. (Hypertension. 2010;55:1418-1424.)
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More than 50% of heart failure (HF) patients presentwithout a major deficit of left ventricular (LV) systolic
function and are presumed to experience HF with normal
ejection fraction (HFNEF). The importance of increased
left-sided filling pressures (FPs) as a pathophysiological
hallmark of HFNEF was reappraised by invasive studies,
which showed a uniform presence at rest of increased FPs1
and which demonstrated increased FPs to limit cardiac
performance during atrial pacing and exercise.2
Arterial hypertension is frequently associated with HFNEF.3,4 It
has been shown that myocardial fibrosis, a common finding
in postmortem studies and endomyocardial biopsies of pa-
tients with hypertensive heart disease,5 participates in the
development of HFNEF in hypertensive patients.6,7 In this
regard, it has been proposed that fibrosis increases myocar-
dial stiffness, which, in turn, reduces LV compliance during
diastole and contributes to elevated FPs in hypertensive
patients.5 However, it is unknown how collagen metabolism
is associated with FPs in hypertensive patients with HFNEF.
Recent clinical investigations have allowed the identifica-
tion of a panel of circulating molecules that fulfil the criteria
to be considered as biomarkers of myocardial collagen metab-
olism in hypertensive patients (reviewed in Reference 8). In
particular, serum carboxy-terminal propeptide of procollagen
type I (PICP) has been characterized as a biomarker of
collagen type 1 synthesis,9 whereas the plasma matrix met-
alloproteinase (MMP) 1:tissue inhibitor of MMP (TIMP)-1
ratio has been shown to be a biomarker of collagen degrada-
tion.7 Although altered levels of serum PICP and plasma
TIMP-1 have been reported recently in hypertensive and
nonhypertensive patients with HFNEF,6,7,10–12 no data are
available on the relationship of the biomarkers with FPs.
Therefore, this study was designed to investigate whether
some association exists between elevated FPs and alterations
of PICP, MMP-1, TIMP-1, and the MMP-1:TIMP-1 ratio in
hypertensive patients with HFNEF.
Methods
Subjects
All of the subjects gave written informed consent to participate in
the study, and the institutional review committee approved the
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study protocol. The study conformed to the principles of the
Helsinki Declaration.
The population was composed of 156 white hypertensive patients
with chronic HF. Arterial hypertension was assessed by repeated
measures of systolic blood pressure and diastolic blood pressure of
139 and/or 89 mm Hg, respectively. Blood pressure was measured
using a mercury sphygmomanometer with an arm cuff appropriate
for each subject. Recordings were made in a sitting position and after
5 minutes at rest on 3 occasions, and the mean of these 3 readings
was recorded. All of the patients underwent appropriate clinical and
laboratory evaluation to exclude secondary hypertension and had a
previous clinical diagnosis of chronic HF on the basis of the presence
of 1 major and 2 minor Framingham criteria,13 in New York Heart
Association (NYHA) functional classes II to IV. None of the patients
studied exhibited LV systolic dysfunction, as assessed by an ejection
fraction 50%. Patients with alcohol abuse, diabetes mellitus,
previous myocardial infarction, segmental abnormalities of wall
motion, aortic stenosis, mitral regurgitation, hypertrophic cardiomy-
opathy, absence of sinus rhythm, and previous treatment with
cardiotoxic drugs were excluded. None of the patients presented
extracardiac conditions associated with alterations in serum or
plasma levels of any of the markers studied (ie, chronic liver disease,
renal insufficiency, or metabolic bone disease). Twenty age- and
sex-matched healthy, normotensive subjects were used as controls
for biochemical parameters.
Echocardiographic Study
2D echocardiographic imaging, targeted M-mode recording, and
Doppler ultrasound measurements were obtained in each patient. LV
mass was measured, and LV mass index (LVMI) was calculated by
dividing LV mass by body surface. The presence of LV hypertrophy
was established when LVMI was 122 g/m2 for women and 149
g/m2 for men.14 LV end-diastolic volume (LVEDV) was calculated
using the Teichholz formula.
The following pulsed Doppler measurements of the mitral flow
were obtained: maximum early transmitral flow velocity in diastole
(E), maximum late transmitral velocity flow in diastole (A), the
deceleration time of the early mitral filling wave (DT), and isovolu-
mic relaxation time (IVRT). Tissue Doppler early mitral annulus
velocity (E) was also assessed. The value of E was averaged from
the measurements performed at the septal and lateral annuli. LV
endocardial fractional shortening and ejection fraction were calcu-
lated according to Quinones et al.15 LV midwall fractional shorten-
ing was calculated according to de Simone et al.16
FPs were derived from estimated pulmonary capillary wedge
pressure (ePCWP). Because an excellent correlation has been ob-
served between the E:E ratio and invasively assessed pulmonary
capillary wedge pressure in patients with a wide range of clinical
conditions and rest ejection fractions, ePCWP was calculated using
the equation ePCWP1.901.24 (E:E).17 Patients were classified
as having normal (ePCWP 15 mm Hg) or elevated (ePCWP
15 mm Hg) FPs.18
Biochemical Determinations
Venous blood samples were obtained in each patient from the left
antecubital vein. PICP was measured in serum by an ELISA method
(Metra Biosystems). The interassay and intra-assay coefficients of
variation were 7.2% and 5.5%, respectively, and the lower detection
limit was 0.2 ng of PICP per milliliter.
MMP-1 and TIMP-1 were measured by ELISA methods (GE
Healthcare). The interassay and intra-assay coefficients of variation
were 11.6% and 5.5% for MMP-1 and 13.1% and 8.9% for TIMP-1,
respectively. The lower detection limits were 1.70 ng of MMP-1 per
milliliter and 125 ng of TIMP-1 per milliliter. Because the actual
activity of MMP-1 depends on the balance between active enzyme
and inhibitors (ie, TIMP-1), the serum MMP-1:TIMP-1 ratio was
considered as an index of MMP-1 activity.19
Amino-terminal propeptide of brain natriuretic peptide (NT-pro-
BNP) was measured in plasma samples by an ELISA method
(Biomedica Gruppe). The interassay and intra-assay coefficients of
variation were 8% and 5%, respectively, and the lower detection
limit was 12 pg of NT-pro-BNP per milliliter.
Statistical Analysis
Clinical differences between the 2 groups of patients were analyzed
by a Student t test for unpaired data once normality was demon-
strated; otherwise, the Mann–Whitney U test was performed. Cate-
gorical variables were evaluated by the 2 test. To analyze the
differences in biochemical markers of collagen metabolism between
control subjects and the 2 groups of patients, 1-way ANOVA
followed by a Student-Newman-Keuls test was performed once
normality was checked (Shapiro-Wilks test); otherwise, the nonpara-
metric Kruskal-Wallis test followed by a Mann–Whitney U test
(adjusting the -level by Bonferroni inequality) was used. The
correlation between continuously distributed variables was tested by
correlation coefficients and univariate regression analysis. The in-
fluence of confounding factors on correlations was excluded by
partial correlation analysis for quantitative parameters and multivar-
iate analysis for qualitative variables. Receiver operating character-
istic (ROC) curves allowed determination of the overall performance
of TIMP-1 and NT-pro-BNP for identifying elevated FPs in the
whole population of patients. Values are expressed as meanSEM.
A value of P0.05 was considered statistically significant.
Results
Clinical Characteristics
The clinical characteristics of the 2 groups of patients are
shown in Table 1. Age was higher in patients with elevated
FPs than in patients with normal FPs. Women were more
predominant in the group of patients with elevated FPs than
in the group of patients with normal FPs. Diastolic blood
pressure was lower and pulse pressure higher in patients with
elevated FPs than in patients with normal FPs. Although the
frequency of patients under treatment with -blockers was
Table 1. Clinical Characteristics in the 2 Groups of Patients
With HF and Normal Ejection Fraction
Parameters
ePCWP 15
mm Hg
ePCWP 15
mm Hg P
Age, y 72.410.95 77.620.97 0.001
Sex, male/female 47/31 25/53 0.001
Body mass index, kg/m2 30.970.62 31.540.57 NS
NYHA functional class 2.210.05 2.460.05 0.01
Blood pressure, mm Hg
Systolic 1472 1523 NS
Diastolic 871 832 0.05
Pulse 602 693 0.05
Heart rate, bpm 792 772 NS
Medications, %
Loop diuretics 76 82 NS
-Blockers 51 31 0.01
ACEIs or ARBs 82 81 NS
Calcium channel blockers 24 18 NS
MR blockers 13 14 NS
NT-pro-BNP, pg/mL 122368 154693 0.05
ACEIs indicates angiotensin-converting enzyme inhibitors; ARBs, angiotensin
receptor blockers; MR, mineralocorticoid receptor; NS, nonsignificant. Values
are expressed as No. or percentage of subjects and as meanSEM.
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higher in patients with normal FPs than in patients with
elevated FPs, no other differences were observed regarding
the remaining classes of drugs. Finally, both the severity of
HF, as assessed by the NYHA functional class, and plasma
NT-pro-BNP were increased in patients with elevated FPs
compared with patients with normal FPs.
Table 2 shows the echocardiographic parameters assessed
in the 2 groups of patients. The values of both LVMI
corrected by LVEDV and relative wall thickness were higher
in patients with elevated FPs than in patients with normal
FPs. The frequency of LV hypertrophy was higher in patients
with elevated FPs than in patients with normal FPs (57%
versus 39%; P0.05). LVEDV corrected by body surface
area was reduced in patients with elevated FPs compared with
patients with normal FPs. The values of ejection fraction, E,
A, deceleration time, the E:E ratio, and ePCWP were
increased in patients with elevated FPs compared with pa-
tients with normal FPs.
Circulating Biomarkers
As shown in Table 3, compared with the control group, serum
PICP and MMP-1 levels were increased in the 2 groups of
patients, with no significant differences between them. Al-
though serum TIMP-1 levels were higher in the 2 groups of
patients than in the control group, the values of this parameter
were increased in patients with elevated FPs compared with
patients with normal FPs. Compared with controls, the serum
MMP-1:TIMP-1 ratio was increased in patients with normal
FPs and remained almost unchanged in patients with elevated
FPs. In addition, this ratio was decreased in patients with
elevated FPs compared with patients with normal FPs.
Figure 1 shows the comparisons of the percentage changes
in the values of the different biomarkers measured in the 2
groups of patients compared with controls. The increase in
serum PICP did tend to be higher in patients with elevated
FPs compared with patients with normal FPs (837% versus
675%). Although the increase in MMP-1 was similar in the
2 groups (19414% versus 20312%), TIMP-1 increased
more in patients with elevated FPs than in patients with
normal FPs (1979% versus 1588%; P0.001). As a
consequence, the increase in the MMP-1:TIMP-1 ratio was
very small in patients with elevated FPs but large in patients
with normal FPs (1.634.68% versus 21.504.78%;
P0.01).
Analysis of Associations
Direct correlations were found among ePCWP and PICP
(r0.185; P0.05), TIMP-1 (r0.349; P0.001; Figure 2),
and NT-pro-BNP (r0.180; P0.05) in all of the patients. In
addition, ePCWP was inversely associated with the MMP-
1:TIMP-1 ratio (r0.240; P0.01; Figure 3). No correla-
tion was found between ePCWP and MMP-1.
Partial correlation analysis evaluated the influence of
potential confounding factors (age, NYHA functional class,
and pulse pressure) in these particular correlations. The
correlation of ePCWP with TIMP-1 was independent of age
(r0.179; P0.05), NYHA functional class (r0.199;
P0.02), and pulse pressure (r0.244; P0.005). In addi-
tion, the correlation of ePCWP with the MMP-1:TIMP-1 ratio
was independent of age (r0.163; P0.05), NYHA func-
tional class (r0.178; P0.05), and pulse pressure
(r0.226; P0.01). In addition, these associations were
independent of sex and therapy with -blockers (P0.01).
A direct correlation was found between NT-pro-BNP and
TIMP-1 (r0.324; P0.001) in all of the patients (Figure 4).
The correlation of NT-pro-BNP with TIMP-1 was indepen-
dent of age (r0.206; P0.05), NYHA functional class
(r0.213; P0.05), and pulse pressure (r0.298; P0.001).
These associations were independent of sex and therapy with
-blockers (P0.05). On the other hand, NT-pro-BNP was
inversely correlated with the MMP-1:TIMP-1 ratio
(r0.187; P0.05). This correlation was independent of
pulse pressure (r0.171; P0.05) but not of age and
NYHA functional class. In addition, the correlation was
independent of sex and therapy with -blockers (P0.05).
Table 2. Cardiac Parameters in the 2 Groups of Patients With
HF and Normal Ejection Fraction
Parameters
ePCWP 15
mm Hg
ePCWP 15
mm Hg P
LVMI, g/m2 125.184.16 143.285.89 NS
Relative wall thickness, mm 0.460.01 0.540.02 0.001
LVEDV, mL 83.435.03 72.427.01 NS
LVESV, mL 33.232.73 26.183.35 0.05
LVEDV/BS, mL/m2 46.032.44 40.813.19 NS
LVMI/LVEDV, g/(m2  mL) 1.760.13 2.760.29 0.01
Ejection fraction, % 64.140.89 67.580.97 0.01
Midwall FS, % 27.161.80 29.131.45 NS
Subendocardial FS, % 38.711.80 40.371.70 NS
E, cm/s 79.642.15 100.233.48 0.001
A, cm/s 80.933.56 98.664.54 0.01
E/A 0.820.05 0.920.05 NS
Isovolumic relaxation time, ms 104.322.30 103.493.23 NS
Deceleration time, ms 208.146.01 226.456.09 0.01
E, cm/s 10.370.43 6.900.19 0.001
E/E 8.030.16 14.790.44 0.001
ePCWP, mm Hg 11.860.20 20.240.55 0.001
LVESV indicates LV end-systolic volume; BS, body surface; FS, fractional
shortening; NS, nonsignificant. Values are expressed as meanSEM.
Table 3. Circulating Biomarkers in Control Subjects and the 2
Groups of Patients With HF and Normal Ejection Fraction
Biomarkers Control
ePCWP 15
mm Hg
ePCWP 15
mm Hg
PICP, ng/mL 67.674.35† 116.603.52 122.424.72
MMP-1, ng/mL 4.820.33† 14.630.59 14.270.67
TIMP-1, ng/mL 58822† 151448 174752§
MMP-1:TIMP-1 (102) 0.830.06* 1.010.04 0.840.03‡
NS indicates nonsignificant. Values are expressed as meanSEM.
*P0.05 vs patients with ePCWP 15 mm Hg.
†P0.001 vs both groups of patients with HFNEF.
‡P0.01 vs patients with ePCWP 15 mm Hg.
§P0.001 vs patients with ePCWP15 mm Hg.
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Analysis of ROC Curves
The ROC curves allowed for determination of the overall
performance of TIMP-1 and NT-pro-BNP for identifying
elevated FPs in hypertensive patients with HFNEF. The area
under the ROC curve was similar for TIMP-1 (0.680.04)
and for NT-pro-BNP (0.620.04), and both curves were
higher (P0.001 and P0.05, respectively) than 0.50. From
the ROC curves, cutoff values of reference for TIMP-1 and
NT-pro-BNP were calculated. The sensitivity and specificity
of each of these 2 values for identifying elevated FPs are
presented in Table 4. Overall, the cutoff value of TIMP-1
showed better specificity and similar sensitivity. The relative
risk of presenting elevated FPs was higher for patients with
TIMP-1 values 1557 ng/mL than for patients with NT-pro-
BNP values 1604 pg/mL (Table 4).
Discussion
The main findings of this study are as follows: (1) serum
PICP and MMP-1 are similarly increased in hypertensive
patients with HFNEF and elevated FPs and in patients with
normal FPs; (2) serum TIMP-1 is more increased in patients
with elevated FPs than in patients with normal FPs; (3) the
MMP-1:TIMP-1 ratio is increased in patients with normal
FPs but is normal in patients with elevated FPs; and (4) serum
TIMP-1 is more accurate than NT-pro-BNP in the discrimi-
nation of elevated FPs in these patients.
It has been observed that, in the setting of steady-state
production by extracardiac sources, serum PICP, MMP-1,
and TIMP-1 detected in peripheral blood from hypertensive
patients are mainly of cardiac origin, because positive gradi-
ents exist for their levels from the coronary sinus toward
antecubital vein, and their peripheral and coronary levels are
highly correlated (reviewed in Reference 8). In addition, it
has been demonstrated in hypertensive patients that serum
PICP is associated with the myocardial activation of the
enzyme responsible of its formation from its procollagen type
I precursor and that the serum MMP-1:TIMP-1 ratio is
associated with the degradation and loss of endomysial and
perimysial collagen (reviewed in Reference 8). Therefore, the
available evidence supports that serum PICP and the MMP-
1:TIMP ratio can be considered as biomarkers of myocardial
collagen type 1 synthesis and degradation, respectively, in
hypertensive patients.
In this conceptual framework, 2 patterns of myocardial
collagen metabolism can be actually distinguished in hyper-
tensive patients with HFNEF from this study: patients with
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normal FPs exhibit a simultaneous increase in the synthesis
and degradation of collagen, and patients with elevated FPs
exhibit the predominance of collagen synthesis over its
degradation. Therefore, the hypothesis emerges that the
alterations of collagen metabolism that would facilitate myo-
cardial fibrosis are detectable just in hypertensive patients
with HFNEF and elevated FPs. This possibility is in agree-
ment with previous findings showing that just two thirds of
patients with HFNEF exhibit myocardial fibrosis in their
endomyocardial biopsies.20 Of interest, LV end-diastolic
pressure and stiffness were significantly higher in patients
with fibrosis than in patients without fibrosis. Furthermore,
significant direct correlations were found between myocar-
dial collagen deposition and LV end-diastolic pressure and
stiffness in all of the patients.
Although myocardial fibrosis can be a key factor in the
increase of myocardial stiffness and the elevation of FPs,
other mechanisms may also contribute to increased stiffness
in HFNEF. For instance, intrinsic cardiomyocyte stiffness is
indeed elevated in patients with HFNEF.20,21 On the other
hand, it has been shown that abnormalities in LV relaxation
may coexist with exaggerated LV stiffness in HFNEF pa-
tients.1 The observation that the value of E, an index of LV
relaxation, is lower in patients with elevated FPs than in
patients with normal FPs adds support to this possibility.
From the reported findings it appears that an excess of
TIMP-1 can determine the development of myocardial fibro-
sis and contribute to the elevation of FPs in hypertensive
patients with HFNEF. Several arguments support this possi-
bility. First, TIMP-1 binds to the active site of MMP-1 in a
1:1 molar ratio and thereby prevents access to substrates.
Thus, the reduced MMP-1:TIMP-1 ratio present in patients
with elevated FPs compared with patients with normal FPs
would suggest that the activity of MMP-1 is lower in the
former than in the latter. Second, TIMP-1 may exert profi-
brotic actions that appear to be independent of any MMP-1
inhibitory effect. For instance, TIMP-1 may stimulate growth
and inhibit apoptosis of fibroblasts, as well as induce the
phenotypic differentiation of these cells into a myofibroblast
phenotype.22 Third, as shown by the ROC curve analysis,
serum TIMP-1 is a sensitive and specific parameter in the
identification of elevated FPs. Fourth, patients with serum
concentrations of TIMP-1 1557 ng/mL have an 	4-fold
higher probability of presenting elevated FPs than subjects
with serum TIMP-1 below this value. Fifth, serum TIMP-1
presents a better performance for estimating elevated FPs
than NT-pro-BNP.
The question emerges as to which factor(s) can be involved
in the additional increase of TIMP-1 seen in patients with
elevated FPs compared with patients with normal FPs. It is
known that TIMP-1 may be induced by several neurohor-
mones and cytokines activated in HF patients.23 In particular,
it has been reported that BNP is involved in the synthesis of
TIMP-1 induced by hypoxia in cardiac fibroblasts.24 In
addition, it has been reported that circulating brain natriuretic
peptide and TIMP-1 are correlated in patients with HF.25 It
can thus be speculated that the excess of NT-pro-BNP present
in patients with elevated FPs compared with patients with
normal FPs may be related to the increase in TIMP-1 seen in
the former compared with the latter. In support of this
possibility, we found that an independent association exists
between NT-pro-BNP and TIMP-1 in the patients from this
study.
Several limitations need to be acknowledged. First, this
was a study involving a relatively small number of hyperten-
sive patients, in whom the severity and duration of hyperten-
sion were not documented, but because of the nature of the
goals under investigation, this design is appropriate. Second,
although our patient sample was composed of hypertensive
patients in whom several cardiac conditions had been ex-
cluded, our results may not be generalized to nonhypertensive
patients with these cardiac conditions. Third, it must be
recognized that therapy may have confounded the findings
and their interpretation. Nevertheless, it has been reported
that treatment with -blockers does not modify the levels of
the analyzed biomarkers of collagen metabolism.26 On the
other hand, the frequencies of medications that have been
demonstrated to influence collagen metabolism in hyperten-
sive patients (eg, the loop diuretic torasemide, angiotensin-
converting enzyme inhibitors and angiotensin receptor block-
ers, and mineralocorticoid receptor blockers),27 were similar
in the 2 groups of patients. Fourth, although the measurement
Log NT-proBNP
Lo
g 
TI
M
P-
1
2.50     2.75 3.00 3.25
3.0
3.2
3.4
3.6 r=0.324
P<0.001
3.753.50
Figure 4. Direct correlation of plasma NT-pro-BNP with serum
TIMP-1 (y0.15x2.74) in all of the patients. NT-pro-BNP and
TIMP-1 levels are represented as log for normalization.
Table 4. Overall Performance of Different Parameters for Predicting Elevated Left-Sided FPs
According to ROC curves
Biomarkers Cutoff Sensitivity Specificity 2 P RR 95% CI
TIMP-1 1557 ng/mL 64 67 15.52 0.001 3.71 1.91 to 7.22
NT-pro-BNP 1604 pg/mL 67 50 4.46 0.05 2.00 1.05 to 3.82
RR indicates relative risk.
1422 Hypertension June 2010
 at UNIVERSIDAD DE NAVARRA on April 30, 2012http://hyper.ahajournals.org/Downloaded from 
of E/E can provide misleading information about FPs in
patients with advanced HF, recent findings indicate that the
measurement remains worthwhile to estimate FPs in patients
with HFNEF.28 Fifth, although ePCWP has been shown to be
highly correlated with actual pulmonary capillary wedge
pressure measured in the catheterization laboratory in HF
patients as those included in this study, its load dependence
must be recognized.17 Sixth, although those clinical condi-
tions that may modify circulating levels of the measured
biomarkers were carefully excluded in the patients enrolled in
the study, we cannot certify that they were in a “steady state”
of extracardiac production of the collagen biomarkers mea-
sured. Finally, we have not assessed additional circulating
biomarkers of collagen metabolism (ie, other collagen-
derived peptides and other MMPs and TIMPs), because there
is not available evidence showing that the biomarkers actu-
ally reflect myocardial collagen metabolism.8
Perspectives
Our findings suggest that a relationship exists between FPs
and the pattern of collagen metabolism in hypertensive
patients with HFNEF. Although in patients with normal FPs
increased collagen synthesis is associated with increased
collagen degradation, in patients with elevated FPs increased
collagen synthesis is accompanied by unchanged collagen
degradation. This metabolic imbalance may facilitate the
development of myocardial fibrosis, which, in turn, may
contribute to increased LV stiffness and elevated FPs in these
patients. It is likely that improved understanding of the
heterogeneity of collagen metabolism in hypertensive pa-
tients with HFNEF will facilitate the development of specific
therapeutic strategies for better protection of the myocardial
structure and the mechanical and functional properties of the
left ventricle. In particular, as recently proposed,29 the time is
coming to exploit novel, clinically relevant strategies for
TIMPs as therapeutic targets in myocardial remodeling. Data
on TIMP-1 here provided can be of particular relevance to
develop pharmacological approaches aimed to prevent myo-
cardial fibrosis and elevated FPs in HFNEF patients.
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